Relay Therapeutics Inc
RLAY8.920USD
+0.770+9.45%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
1.54BValor de mercado
PerdaP/L TTM
Mais detalhes de Relay Therapeutics Inc Empresa
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Informações de Relay Therapeutics Inc
Código da empresaRLAY
Nome da EmpresaRelay Therapeutics Inc
Data de listagemJul 16, 2020
CEOPatel (Sanjiv K)
Número de funcionários261
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 16
Endereço60 Hampshire Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139
Telefone16173708837
Sitehttps://relaytx.com/
Código da empresaRLAY
Data de listagemJul 16, 2020
CEOPatel (Sanjiv K)
Executivos da empresa Relay Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-19913.00%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
120.71K
-13038.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexis A. Borisy
Mr. Alexis A. Borisy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-19913.00%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
120.71K
-13038.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Detalhamento da receita
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: ter, 18 de nov
Atualizado em: ter, 18 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
Outro
52.98%
Investidores
Investidores
Proporção
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
Outro
52.98%
Tipos de investidores
Investidores
Proporção
Hedge Fund
36.60%
Investment Advisor
27.59%
Private Equity
16.70%
Investment Advisor/Hedge Fund
12.95%
Research Firm
2.08%
Individual Investor
1.27%
Venture Capital
0.91%
Sovereign Wealth Fund
0.48%
Family Office
0.38%
Outro
1.05%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
457
170.34M
98.28%
-42.79M
2025Q3
457
168.31M
97.11%
-38.09M
2025Q2
460
180.78M
105.44%
-7.40M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
SB Investment Advisers (UK) Limited
27.90M
16.1%
--
--
Sep 30, 2025
Commodore Capital LP
17.00M
9.81%
+3.65M
+27.34%
Sep 30, 2025
Point72 Asset Management, L.P.
14.77M
8.52%
+1.33M
+9.88%
Sep 30, 2025
Casdin Capital, LLC
11.34M
6.54%
-57.19K
-0.50%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.48M
6.05%
-143.98K
-1.35%
Sep 30, 2025
The Vanguard Group, Inc.
9.37M
5.4%
+15.89K
+0.17%
Sep 30, 2025
Bellevue Asset Management AG
8.35M
4.82%
+114.74K
+1.39%
Sep 30, 2025
Tang Capital Management, LLC
8.07M
4.65%
--
--
Sep 30, 2025
State Street Investment Management (US)
5.07M
2.92%
-136.80K
-2.63%
Sep 30, 2025
Nextech Invest, Ltd.
3.85M
2.22%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Tema Oncology ETF
0.98%
ALPS Medical Breakthroughs ETF
0.51%
State Street SPDR S&P Biotech ETF
0.33%
ProShares Ultra Nasdaq Biotechnology
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Avantis US Small Cap Equity ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
iShares Biotechnology ETF
0.08%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.4%
Tema Oncology ETF
Proporção0.98%
ALPS Medical Breakthroughs ETF
Proporção0.51%
State Street SPDR S&P Biotech ETF
Proporção0.33%
ProShares Ultra Nasdaq Biotechnology
Proporção0.17%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.16%
Avantis US Small Cap Equity ETF
Proporção0.14%
Invesco Nasdaq Biotechnology ETF
Proporção0.12%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.09%
iShares Biotechnology ETF
Proporção0.08%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
